Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to treat hypertension and related comorbidities including chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone. The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is advancing this therapeutic approach through clinical development to address unmet medical needs in cardiovascular and renal disease management.
Industry
Biopharmaceutical
Remote Policy
Fully Remote
Beta · Sourced from candidate reports
Be the first to share your experience with Mineralys Therapeutics.
Your reply helps other candidates know what to expect.
